DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

[Objectives] To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. [Methods] A multicent...

Descripción completa

Detalles Bibliográficos
Autores: Hidalgo-Tenorio, Carmen, Vinuesa García, David, Plata-Ciezar, Antonio, Martín-Dávila, Pilar, Iftimie, Simona, Sequera, Sergio, Loeches, Belén, López-Cortés, Luis Eduardo, Fariñas, María del Carmen, Fernández-Roldán, Concepción, Javier-Martinez, Rosario, Muñoz García, Patricia, Arenas-Miras, Maria del Mar, Martínez-Marcos, Francisco Javier, Miró, José María, Herrero-Rodríguez, Carmen, Bereciartúa, Elena, De Jesus, Samantha E., Pasquau-Liaño, Juan
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/212324
Acceso en línea:http://hdl.handle.net/10261/212324
Access Level:acceso abierto
Palabra clave:Endocarditis
Bloodstream infections
Dalbavancin
id ES_3471969302cd68e5eeefdbeb852548cd
oai_identifier_str oai:digital.csic.es:10261/212324
network_acronym_str ES
network_name_str España
repository_id_str
spelling DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocciHidalgo-Tenorio, CarmenVinuesa García, DavidPlata-Ciezar, AntonioMartín-Dávila, PilarIftimie, SimonaSequera, SergioLoeches, BelénLópez-Cortés, Luis EduardoFariñas, María del CarmenFernández-Roldán, ConcepciónJavier-Martinez, RosarioMuñoz García, PatriciaArenas-Miras, Maria del MarMartínez-Marcos, Francisco JavierMiró, José MaríaHerrero-Rodríguez, CarmenBereciartúa, ElenaDe Jesus, Samantha E.Pasquau-Liaño, JuanEndocarditisBloodstream infectionsDalbavancin[Objectives] To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. [Methods] A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. [Results] Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). [Conclusions] DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.BioMed CentralConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2020202020192020info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/212324reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1186/s12941-019-0329-6Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2123242026-05-22T06:33:51Z
dc.title.none.fl_str_mv DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
spellingShingle DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Hidalgo-Tenorio, Carmen
Endocarditis
Bloodstream infections
Dalbavancin
title_short DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title_full DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title_fullStr DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title_full_unstemmed DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
title_sort DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
dc.creator.none.fl_str_mv Hidalgo-Tenorio, Carmen
Vinuesa García, David
Plata-Ciezar, Antonio
Martín-Dávila, Pilar
Iftimie, Simona
Sequera, Sergio
Loeches, Belén
López-Cortés, Luis Eduardo
Fariñas, María del Carmen
Fernández-Roldán, Concepción
Javier-Martinez, Rosario
Muñoz García, Patricia
Arenas-Miras, Maria del Mar
Martínez-Marcos, Francisco Javier
Miró, José María
Herrero-Rodríguez, Carmen
Bereciartúa, Elena
De Jesus, Samantha E.
Pasquau-Liaño, Juan
author Hidalgo-Tenorio, Carmen
author_facet Hidalgo-Tenorio, Carmen
Vinuesa García, David
Plata-Ciezar, Antonio
Martín-Dávila, Pilar
Iftimie, Simona
Sequera, Sergio
Loeches, Belén
López-Cortés, Luis Eduardo
Fariñas, María del Carmen
Fernández-Roldán, Concepción
Javier-Martinez, Rosario
Muñoz García, Patricia
Arenas-Miras, Maria del Mar
Martínez-Marcos, Francisco Javier
Miró, José María
Herrero-Rodríguez, Carmen
Bereciartúa, Elena
De Jesus, Samantha E.
Pasquau-Liaño, Juan
author_role author
author2 Vinuesa García, David
Plata-Ciezar, Antonio
Martín-Dávila, Pilar
Iftimie, Simona
Sequera, Sergio
Loeches, Belén
López-Cortés, Luis Eduardo
Fariñas, María del Carmen
Fernández-Roldán, Concepción
Javier-Martinez, Rosario
Muñoz García, Patricia
Arenas-Miras, Maria del Mar
Martínez-Marcos, Francisco Javier
Miró, José María
Herrero-Rodríguez, Carmen
Bereciartúa, Elena
De Jesus, Samantha E.
Pasquau-Liaño, Juan
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Endocarditis
Bloodstream infections
Dalbavancin
topic Endocarditis
Bloodstream infections
Dalbavancin
description [Objectives] To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. [Methods] A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. [Results] Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). [Conclusions] DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/212324
url http://hdl.handle.net/10261/212324
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1186/s12941-019-0329-6
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405818013614080
score 15.812429

Similares en LA Referencia